VIDEO: Patient reported outcomes define pathway for fatty liver treatment

BOSTON — In this exclusive video from The Liver Meeting 2019, Zobair M. Younossi, MD, chairman of the department of medicine at Inova Fairfax Hospital in Virginia, provides an overview of patient reported outcomes from several studies of emerging nonalcoholic fatty liver disease and nonalcoholic steatohepatitis therapies.

“A highlight from our group was the importance of nonalcoholic fatty liver disease from a global perspective,” Younossi told Healio Gastroenterology and Liver Disease. “Data from a global registry of nonalcoholic steatohepatitis that’s maintained by us, suggests that nonalcoholic fatty liver disease is a very important liver disease across the world and that patient characteristics are different when you look at different regions of the world.”

Younossi continued to explain that the differences between patient reported outcomes from clinical trials and from real-world settings can provide incentive to develop strategies for generalizing expected outcomes.

Additionally, he highlighted that while liver disease-related mortality rates have fluctuated across the globe, mortality related to NAFLD has continued to increase.

Reference:

Paik J, et al. Abstract 0126. Presented at: The Liver Meeting; Nov. 7-12, 2019; Boston.

Younossi ZM, et al. Abstract 0056. Presented at: The Liver Meeting; Nov. 7-12, 2019; Boston.

Younossi ZM, et al. Abstract 0747. Presented at: The Liver Meeting; Nov. 7-12, 2019; Boston.

Younossi ZM, et al. Abstract 0886. Presented at: The Liver Meeting; Nov. 7-12, 2019; Boston.

Younossi ZM, et al. Abstract 1242. Presented at: The Liver Meeting; Nov. 7-12, 2019; Boston.

Younossi ZM, et al. Abstract 1864. Presented at: The Liver Meeting; Nov. 7-12, 2019; Boston.

Disclosure: Younossi reports he is a consultant for AbbVie, Bristol-Myers Squibb, Gilead, Intercept, Merck, Novartis, Novo Nordisk, Siemens, Shinogi, Terns and Viking.